Fresh vs Frozen Embryo Transfer: Which Fits Your IVF Cycle?
Key Takeaways
Neither option is better for every patient. Freeze-all helps most when OHSS risk is high, embryo testing (PGT) is planned, or the lining is not ready. Fresh transfer can still fit when response, progesterone, and the lining look good. In women with a low chance of success, one 2025 randomised trial found fewer live births after routine freeze-all than after fresh transfer.
Key evidence: ESHRE ovarian stimulation guideline (2025) Cochrane review of fresh versus frozen transfer (2021) Low-prognosis randomised trial (2025)
Fresh vs Frozen Embryo Transfer (FET): Which Option Fits Your Cycle?
This video is in French. Check YouTube player settings for available translated audio tracks or subtitles.
During IVF, patients often hear two opposite messages: that a fresh transfer is more “natural”, or that a frozen transfer is more advanced and therefore better. Both shortcuts miss the real decision.
A fresh transfer places an embryo in the uterus a few days after egg retrieval. A frozen embryo transfer (FET) uses an embryo that has been vitrified — frozen very rapidly — and is transferred in a later cycle. The difference is not simply the date: the hormonal setting, safety considerations, laboratory plan, and reason for waiting all matter.
A more useful question is: what are we trying to solve in this particular cycle? Ovarian response, risk of ovarian hyperstimulation syndrome (OHSS — ovaries swell and fluid can build up after a strong stimulation), progesterone timing, the endometrium (the uterine lining), embryo testing, and the number of available embryos all help answer it.
On this page:
- Understand the three decisions
- When fresh transfer may fit
- When freeze-all has a clear purpose
- What the evidence says about success
- How a later FET cycle is prepared
- Pregnancy and newborn outcomes
- Timing, cost, and international planning
- Questions to take into the consultation
- Frequently Asked Questions for Dr. Aksoy
Fresh transfer, FET, and freeze-all are three different decisions
A fresh transfer happens in the egg-retrieval cycle. FET happens later. “Freeze-all” is the decision to postpone transfer and vitrify every suitable embryo from that retrieval; it is not the name of every frozen transfer.
| Decision point | Fresh transfer | Frozen embryo transfer |
|---|---|---|
| Timing | Same stimulation cycle as egg retrieval | A later natural, modified-natural, or programmed cycle |
| Hormonal setting | Endometrium is exposed to stimulation hormones | Stimulation and transfer are separated |
| OHSS | An early pregnancy can prolong or worsen OHSS | Freeze-all allows recovery before pregnancy |
| PGT | Usually not compatible with the time needed for results | Commonly used while biopsy results are pending |
| Time and steps | Faster route to the first pregnancy test | Adds freezing, storage, thawing, and another cycle |
Vitrification has made embryo freezing and warming reliable in experienced laboratories. It remains a biological process: most embryos survive warming, but survival is not guaranteed for every embryo. When only one or two embryos are available, that small risk can weigh more heavily in the plan.
When a fresh transfer can be reasonable
A fresh transfer is a reasonable choice when nothing in the cycle calls for waiting. In practice, that usually means:
- the ovarian response is controlled rather than excessive;
- OHSS risk is low;
- progesterone has not risen prematurely;
- the endometrium appears suitable;
- PGT is not planned; and
- there is no uterine or medical reason to postpone pregnancy.
Fresh transfer deserves particular consideration when the prognosis is low or only a few embryos are expected. A 2025 randomised trial in nine Chinese centres assigned 838 women with low prognosis, by random draw, to freeze-all or fresh transfer. Low prognosis here meant nine or fewer eggs retrieved, or a poor ovarian reserve. The first transfer led to a live birth (a baby born alive) in 32% with freeze-all and 40% with fresh transfer. Cumulative live birth (a baby from any of the embryos from that retrieval) was also lower with freeze-all: 44% versus 51%.
Those figures describe the trial groups. They do not predict one patient’s result. They do challenge the idea that routine freezing is always harmless when there is no clear reason for it.
When freezing all embryos may be useful
Freeze-all is most useful when waiting for the transfer solves a specific problem. It is a reasoned choice, not a default. Common reasons include:
- high ovarian response or a meaningful risk of OHSS;
- an early progesterone rise or an endometrium that is not suitable for transfer;
- PGT, because the embryo is usually vitrified while results are processed;
- a uterine finding that should be assessed or treated first;
- an acute medical issue that makes pregnancy inadvisable in the current cycle; or
- a practical need to separate retrieval and transfer.
The safety indication deserves particular attention. For women at risk of OHSS, the 2025 ESHRE ovarian stimulation guideline recommends freeze-all to lower the risk of late-onset OHSS; it is a strong recommendation, but it rests on low-certainty evidence. A Cochrane review of randomised studies also found less OHSS with freeze-all (about 1% versus 3%, low-certainty evidence). For the broader IVF population, the same review found probably little or no difference in cumulative live birth (see the success section below).
PGT
Embryo biopsy results are usually not available in time for a fresh transfer. Suitable embryos are therefore vitrified while the result is processed. Here, freezing is part of the laboratory pathway rather than a claim that frozen transfer is inherently more successful.
PMOS, a high response, and OHSS risk
PMOS (polyendocrine metabolic ovarian syndrome, formerly PCOS) can increase the chance of a high ovarian response, but the diagnosis alone does not make freeze-all compulsory. The actual response and the patient’s OHSS risk matter. In a younger patient with a high ovarian response and a clinically meaningful risk, avoiding an immediate pregnancy can prevent late OHSS from developing or becoming more severe.
Endometriosis
Endometriosis also requires a case-by-case decision. A later transfer may be useful when there is a separate reason to postpone pregnancy or when the endometrial and inflammatory context needs attention first. This is not the same as recommending freeze-all or prolonged medical pretreatment for every patient with endometriosis.
Clinical Note
“When vitrification became reliable, there was a period when routine frozen transfer was expected to improve results by allowing better endometrial preparation. Later studies, and what we observed in practice, did not show a universal advantage. We therefore do not offer freeze-all to everyone. We use it when there is a clear reason: for PGT; for women with PMOS or young high responders at risk of OHSS; and for selected patients with endometriosis when transfer should be delayed while the endometrial and inflammatory context is addressed. OHSS should not be underestimated; it can be serious and very burdensome. For patients at meaningful risk, freezing all embryos is an important safety strategy.”
— Dr. Senai Aksoy, first-hand clinical observation originally verified 14 July and reconfirmed 25 August 2026
This is a clinical practice observation. It does not prove that every patient with endometriosis benefits from freeze-all or medical pretreatment. The ESHRE endometriosis guideline recommends against prolonged GnRH-agonist pretreatment to improve live birth, because the benefit is uncertain. It also finds too little evidence to recommend prolonged pretreatment with progestogens or the combined contraceptive pill for that purpose.
Evidence box: endometriosis, freeze-all, and pretreatment
A meta-analysis of six studies covering 3,010 women — earlier comparisons pooled together, not a new randomised trial — reported more live births after frozen than fresh transfer in women with endometriosis. The authors called the evidence “not yet abundant” and asked for more rigorous studies. That is why endometriosis alone is not treated here as a standing order for freeze-all.
Does freeze-all improve the chance of a baby?
Not for everyone. Freeze-all can make a high-risk cycle safer, but it does not reliably raise cumulative live birth across the general IVF population.
In the Cochrane review, freeze-all probably made little or no difference to cumulative live birth or to ongoing pregnancy (a pregnancy that continues beyond the early weeks). It also delays the first transfer, so time to pregnancy can be longer even when the long-run chance of a baby is similar.
Results still vary by patient group. Some earlier trials in selected good-prognosis, ovulatory patients found higher live birth after frozen single-blastocyst transfer. The low-prognosis trial above pointed the other way. Those findings look contradictory only if the populations are ignored.
Age, embryo quality, how many embryos can be transferred, and laboratory performance remain major drivers of outcome. Published IVF success rates describe groups of patients. They are not a personal forecast.
Evidence box: cumulative success trials
The Cochrane analysis for the cumulative outcome included eight randomised studies and 4,712 women. The E-Freeze randomised trial likewise found no evidence that routine freeze-all improved the healthy baby rate (a live, singleton, full-term baby of suitable weight). It enrolled couples under 42 with at least three good-quality embryos. It did not reach its planned sample size, and about one in five couples did not follow the group they were assigned to, so it does not settle every subgroup question.
If FET is chosen, the preparation protocol is a second decision
A frozen embryo can be transferred in a natural, modified-natural, or programmed cycle. The right option depends on ovulation, medical history, monitoring, and practical constraints. Current trials do not support one universal protocol for every ovulatory patient.
In a natural cycle, the body ovulates on its own. In a modified-natural cycle, an ovulation trigger is added. In a programmed cycle, estrogen and progesterone prepare the lining without relying on ovulation. These approaches do not create the same hormonal environment.
Observational evidence has linked programmed cycles — which may have no corpus luteum (the structure that normally supports early pregnancy hormones) — with more hypertensive disorders of pregnancy than natural-cycle FET. Pregnancy rates are closer between protocols; the differences reported most often concern complications.
Our guide to endometrial preparation for FET explains the options in more detail.
Evidence box: natural versus programmed FET preparation
A systematic review of observational studies — a structured search that pools the studies it finds — associated programmed cycles with more hypertensive disorders of pregnancy than natural-cycle FET; evidence on reproductive outcomes was less settled. A 2025 open-label trial reported more live births with a strategy starting in a natural cycle, but substantial crossover between groups limited certainty. A 2026 multicentre randomised trial found similar clinical pregnancy rates (pregnancy confirmed with a fetal heartbeat on scan) after natural- and artificial-cycle preparation; it was not designed to show a live-birth difference. A larger 2026 BMJ randomised trial assigned 4,376 ovulatory women to natural-ovulation or programmed preparation: healthy live birth rates were similar (41.6% versus 40.6%), several maternal complications were less frequent with natural ovulation, and cycle cancellation was more common in that group.
Pregnancy and newborn outcomes
Both approaches have reassuring outcomes overall, but their population-level risk patterns differ. There is no simple “safer for everyone” ranking.
A 2024 systematic review of neonatal outcomes found that fresh transfer was associated with more preterm birth, low birth weight, and small-for-gestational-age birth. FET was associated with more large-for-gestational-age birth and macrosomia. The review did not find a significant difference in congenital anomalies or neonatal death.
Some of the higher hypertensive risk reported after FET may relate to the preparation protocol rather than freezing itself. Much of this evidence is observational: it can show an association without proving that the transfer method alone caused the outcome. Age, blood pressure, metabolic health, and the FET protocol still belong in the individual assessment.
Timing, cost, and international planning
Fresh transfer is usually faster. Freeze-all adds another cycle and may add cost or travel, although the pause can sometimes make recovery and scheduling easier.
Fresh transfer can shorten the path to the first pregnancy test. Freeze-all adds laboratory freezing, storage, warming, medication or monitoring in another cycle, and usually an additional visit. These steps may add cost and emotional burden. For some people, the extra wait is a minor inconvenience. For others, it is one of the hardest parts of the plan and deserves to be discussed openly.
For international patients, a later FET may simplify recovery after egg retrieval or create a more predictable transfer window, but it can also require a second trip. The medical indication should be decided first; travel planning should then support that plan rather than determine it.
Questions to discuss before deciding
A useful consultation should explain why transfer is being done now or later, what evidence applies to the patient’s situation, and what each option changes beyond the pregnancy rate.
Before choosing fresh transfer or freeze-all, ask:
- Is my response high enough to create a clinically important OHSS risk?
- Are progesterone and the endometrium suitable for transfer now?
- Is PGT planned, and when will the result be available?
- How many embryos are likely to be available for transfer or freezing?
- If FET is planned, am I a candidate for a natural or modified-natural cycle?
- What will each option change in time, medication, visits, and cost?
The plan may change as the stimulation cycle unfolds. That flexibility is how the team responds safely to the information available on the day. The embryo transfer procedure itself is only one part of the decision.
Frequently Asked Questions for Dr. Aksoy
Is fresh embryo transfer better than frozen?
When the lining and hormone values look suitable, I do not think every patient needs embryos frozen. Fresh day-5 transfer is a perfectly good option for many patients. What changes my decision most are the progesterone level on the trigger day, how the ovaries responded to stimulation, OHSS risk, and whether the endometrium is truly ready for transfer. If progesterone rose early, OHSS risk is high because of an exaggerated response, or I find something such as fluid in the cavity that could harm implantation, I prefer to freeze and transfer in a later cycle.
If hormones are suitable, the lining is adequate, and OHSS risk is low, I do not abandon fresh transfer only because frozen transfer is thought to be more successful. Applying freeze-all to everyone has not been shown to raise live-birth rates. What matters is not insisting on fresh or frozen, but choosing the right timing for that patient.
When do you recommend freeze-all?
We do not offer freeze-all to everyone. We use it when there is a clear reason: for PGT, for women with PMOS or young high responders at risk of OHSS, and for selected patients with endometriosis. Where the OHSS risk is meaningful, freezing all embryos is an important safety strategy. The Clinical Note above explains our reasoning in more detail.
Are frozen embryos less successful than fresh ones?
No. The fact that an embryo has been frozen does not, on its own, mean a lower chance of success. With vitrification, the great majority of embryos come through thawing in good condition, but we cannot guarantee that every embryo will survive. The chance of success still depends on the quality of the eggs at the age the embryos were obtained, on the characteristics of the embryo, and on factors related to the uterus.
Sources
- European Society of Human Reproduction and Embryology. “Ovarian Stimulation for IVF/ICSI: Guideline Update 2025.” ESHRE ovarian stimulation guideline
- European Society of Human Reproduction and Embryology. “ESHRE Guideline: Endometriosis.” 2022. ESHRE endometriosis guideline
- Zaat T et al. “Fresh versus frozen embryo transfers in assisted reproduction.” Cochrane Database of Systematic Reviews, 2021. PubMed
- Chang Y et al. “Association of embryo transfer type with infertility in endometriosis: a systematic review and meta-analysis.” Journal of Assisted Reproduction and Genetics, 2022. PubMed
- Wei D et al. “Frozen versus fresh embryo transfer in women with low prognosis for in vitro fertilisation treatment: pragmatic, multicentre, randomised controlled trial.” BMJ, 2025. PubMed
- Maheshwari A et al. “Transfer of thawed frozen embryo versus fresh embryo to improve the healthy baby rate in women undergoing IVF: the E-Freeze RCT.” Health Technology Assessment, 2022. PubMed
- Tocariu R et al. “Fresh versus frozen embryo transfer in IVF/ICSI cycles: a systematic review and meta-analysis of neonatal outcomes.” Medicina, 2024. PubMed
- Zaat TR et al. “Obstetric and neonatal outcomes after natural versus artificial cycle frozen embryo transfer and the role of luteal phase support: a systematic review and meta-analysis.” Human Reproduction Update, 2023. PubMed
- Liu X et al. “Natural cycle versus hormone replacement therapy as endometrial preparation in ovulatory women undergoing frozen-thawed embryo transfer: the COMPETE open-label randomized controlled trial.” PLOS Medicine, 2025. PubMed
- Geysenbergh B et al. “Natural versus artificial cycle for endometrial preparation in ovulatory women undergoing frozen-thawed embryo transfer: a randomised controlled trial.” Human Reproduction, 2026. PubMed
- Wei D et al. “Natural ovulation versus programmed regimens before frozen embryo transfer in ovulatory women: multicentre, randomised clinical trial.” BMJ, 2026. BMJ
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.